Floatz logo

Recombinant Human Interleukin-15

Stage IIIA Cutaneous Melanoma AJCC v7

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

152 Active assets in the Stage IIIA Cutaneous Melanoma AJCC v7 cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

Recombinant Human Interleukin-15 is also rated in:

clear cell renal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Sezary syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
mycosis fungoidesDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →